Viridian Therapeutics (VRDN) Stock Analysis

What Viridian Therapeutics does

Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.

Key metrics

ETFs linked to VRDN

Broad-market and Healthcare sector ETFs an investor holding Viridian Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how VRDN fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Viridian Therapeutics?

Viridian Therapeutics trades under the ticker VRDN on NASDAQ.

Which exchange is VRDN listed on?

VRDN is listed on NASDAQ.

What sector does Viridian Therapeutics operate in?

Viridian Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze VRDN in a portfolio?

PortView shows VRDN's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.